An interventional study of Fish oil capsules and High-oleic safflower oil capsules in Extracellular Vesicles; Generation and Function, sponsored by University of Reading. Completed at 1 site in United Kingdom. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by University of Reading · Not applicable, Interventional, and Prevention
N-3 polyunsaturated fatty acids (n-3 PUFA), which are abundant in oily fish and fish oils, have been suggested to play a role in reducing the risk of cardiovascular diseases (CVDs) by modifying a wide range of risk factors, such as blood fats, blood clotting, blood vessel function and inflammation. Extracellular vesicles (EVs) are small particles released from various cells when they are activated or damaged. High numbers of EVs in the blood have been associated with a higher risk of CVDs, and it is thought that this is because they carry 'bioactive' components which can affect many processes involved in CVDs. However, very few clinical trials have investigated the relationships between the consumption of n-3 PUFA and circulating EVs. This study aims to investigate the effects of dietary n-3 PUFA on the generation and functional activities of EVs, which would provide new insight into the benefits of n-3 PUFA on cardiovascular health.
The proposed study will be a randomised, double-blind, placebo-controlled crossover intervention. Subjects (40-70y) at moderate CVDs risk will be supplemented with either fish oil (1.8 g/d n-3 PUFA) or placebo (high-oleic safflower oil) for 12 weeks. After a 12-week washout and then cross-over to the other intervention for another 12 weeks. Blood samples will be collected before and after each intervention. A food frequency questionnaire will be administered to assess the subject's habitual intake of n-3 PUFA. Subjects will also be expected to maintain a low consumption of n-3 fatty acids, refrain from the use of all supplements, and maintain their body weight during the study. The dose is based on our previous work, which demonstrated a reduction in numbers of endothelial-derived EVs (EEVs) and a trend for reduced numbers of platelet-derived EVs (PEVs), and a dose at which beneficial effects of n-3 PUFA on plaque stability are reported. The experimental work will follow two main strands. The first strand will examine the influence of n-3 PUFA supplementation on the characteristics and functional activities of total EVs from plasma. The second strand will examine the influence of n-3 PUFA on the generation of PEVs from platelets taken from subjects and stimulated in vitro; the PEVs generated will subsequently be assessed for their composition and functional activity. This experimental design will allow simultaneous investigation of both the composition and activity of total EVs taken directly from blood, and the generation and activity of PEVs. Based on our previous work, 27 subjects are required to detect a 10% reduction in numbers of EVs following fish oil supplementation with a two-sided significance level of 5% and a power of 90%, and 34 subjects are required for a power of 95%. Also based on previous data, 22 subjects would give 95% power to detect 10% differences in thrombus formation and 30 subjects are required to detect a significant effect of n-3 PUFA on platelet aggregation and phosphatidylserine (PS) exposure. Allowing for a 15% dropout rate, and aiming for 95% power based on a 10% reduction in EVs numbers, we will therefore recruit 40 subjects in total.
At moderate risk of cardiovascular diseases
Exclusion Criteria:
Fish oil capsules
Dietary Supplement: Fish oil capsules
High-oleic safflower oil capsules
Dietary Supplement: High-oleic safflower oil capsules
Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
High-oleic safflower oil capsules for 12 weeks
Numbers of Circulating Total EVs in Platelet-free Plasma (PFP) Detected by Nanoparticle Tracking Analysis (NTA)
Circulating EVs were first isolated to obtain fractions 7\~9 by size exclusion chromatography (SEC) using Izon qEV columns (Izon Science Ltd, Oxford, United Kingdom). Fractions were then diluted with PBS to maintain the recommended concentration range of particles (1\~10\*10\^8 vesicles/ml) before being analysed on NanoSight 300 (Malvern, Amesbury, United Kingdom). For each analysis, five videos, each of 60 seconds duration, were captured with the camera level at 13. Data were analysed using the instrument software NTA 3.20, which can identify individual particles and estimate their sizes based on the Stokes-Einstein Equation. Finally, a threshold of 70nm was set for NTA to ensure minimal interference by small lipoproteins.
Time frame: Change of circulating total EV numbers in PFP detected by NTA after intake period of 12 weeks
Numbers of Total Phosphatidylserine Positive EVs (PS+EVs) in Platelet-free Plasma (PFP) Detected by Flow Cytometry (FCM)
A 5μl of PFP was added into nonsticky microcentrifuge tubes (Alpha Laboratories Ltd, Hampshire, United Kingdom), which contained 5μl FcR blocking reagent (Miltenyi Biotec Ltd, Surrey, United Kingdom) and Annexin V buffer and incubated for 15 minutes in the dark at room temperature. Antibodies and isotype-matched controls were then added and samples incubated for another 15 minutes in the dark at room temperature. After incubation, samples were diluted with 200μl Annexin V buffer and transferred into FACS flow tubes (BD Biosciences, Wokingham, United Kingdom), ready to be analysed by FCM. PS+EVs were identified as Annexin V+EVs when triggering on APC fluorescence.
Time frame: Change of total PS+EV numbers in PFP detected by FCM after intake period of 12 weeks
Characterisation of Circulating EVs Subpopulation in PFP Detected by Fluorescence FCM
A 5μl of PFP was added into nonsticky microcentrifuge tubes (Alpha Laboratories Ltd, Hampshire, United Kingdom), which contained 5μl FcR blocking reagent (Miltenyi Biotec Ltd, Surrey, United Kingdom) and Annexin V buffer and incubated for 15 minutes in the dark at room temperature. Antibodies and isotype-matched controls were then added and samples incubated for another 15 minutes in the dark at room temperature. After incubation, samples were diluted with 200μl Annexin V buffer and transferred into FACS flow tubes (BD Biosciences, Wokingham, United Kingdom), ready to be analysed by FCM. Platelet-derived EVs (PDEVs) were identified as Annexin V+EVs which also stained positive for CD41-PE in APC vs PE quadrant plot, and endothelial-derived EVs (EDEVs) were identified as Annexin V+EVs which also stained positive for CD105- eFluor450 in APC vs PB quadrant plot.
Time frame: Change in the numbers of circulating EVs subpopulation in PFP by fluorescence FCM after intake period of 12 weeks
Pro-thrombotic Activities of Circulating EVs in PFP (Lag Time for Thrombin Generation)
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
Time frame: Change of pro-thrombotic activities (lag time for thrombin generation)of circulating EVs in PFP after intake period of 12 weeks
Pro-thrombotic Activities of Circulating EVs in PFP (Peak Thrombin Concentration)
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
Time frame: Change of pro-thrombotic activities (peak thrombin concentration) of circulating EVs in PFP after intake period of 12 weeks
Pro-thrombotic Activities of Circulating EVs in PFP (Time to Peak Thrombin Concentration)
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
Time frame: Change of pro-thrombotic activities (time to peak thrombin concentration) of circulating EVs in PFP after intake period of 12 weeks
Pro-thrombotic Activities of Circulating EVs in PFP (Velocity Index)
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
Time frame: Change of pro-thrombotic activities (velocity index) of circulating EVs in PFP after intake period of 12 weeks
Pro-thrombotic Activities of Circulating EVs in PFP (Endogenous Thrombin Potential)
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
Time frame: Change of pro-thrombotic activities (endogenous thrombin potential) of circulating EVs in PFP after intake period of 12 weeks
Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay
96-well high-throughput aggregometry technique, allowing testing of a wide range of concentrations of different agonists, was used to examine the influence of n-3 PUFA supplementation on platelet function. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) from each study visit was used in the platelet aggregation assay using pre-prepared 96-well microplates, containing the agonists (ADP, EPI, TRAP-6 and U46619). Dose-response curves in response to each agonist were obtained and results were represented as a LogEC50 (log concentration of agonist, M, giving a response halfway between maximum and minimum aggregation).
Time frame: Change in ex vivo platelet activation after intake period of 12 weeks
Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay (CRP-XL Log EC50)
96-well high-throughput aggregometry technique, allowing testing of a wide range of concentrations of different agonists, was used to examine the influence of n-3 PUFA supplementation on platelet function. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) from each study visit was used in the platelet aggregation assay using pre-prepared 96-well microplates, containing the agonists (CRP-XL). Dose-response curves in response to each agonist were obtained and results were represented as a LogEC50 (log concentration of agonist, mg/ml, giving a response halfway between maximum and minimum aggregation).
Time frame: Change in ex vivo platelet activation after intake period of 12 weeks
Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Endpoint and Maximum of Thrombus Formation)
Ex vivo thrombus formation was measured by the addition of in vitro-generated PDEVs from stimulated platelets into whole blood under flow. Results were presented as three variables: (i) endpoint for ex vivo thrombus formation (FU); (ii) endpoint for ex vivo thrombus formation (FU); (iii) area under curve.
Time frame: Change in pro-thrombotic activities (endpoint and maximum of thrombus formation)of PEVs prepared from the supernatants of stimulated platelets after intake period of 12 weeks
Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Area Under Curve)
Ex vivo thrombus formation was measured by the addition of in vitro-generated PDEVs from stimulated platelets into whole blood under flow. Results were presented as three variables: (i) endpoint for ex vivo thrombus formation (FU); (ii) endpoint for ex vivo thrombus formation (FU); (iii) area under curve.
Time frame: Change in pro-thrombotic activities (area under curve) of PEVs prepared from the supernatants of stimulated platelets after intake period of 12 weeks
Circulating EV Total Lipids Analysis
A 500μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and subjected to SEC for the isolation and purification of EVs. The fractions 7\~9 were pooled together, and 800μl of pooled fractions was prepared for total lipid extraction and methyl esterification. The EV total lipid methyl esters were then analysed by gas chromatography on a Hewlett-Packard 6890 series GC (Hewlett-Packard, California, United States), with the following protocol: split ratio was set as 30:1 for plasma and EV analysis. The injection volume was 1μl for plasma and 5μl for EVs, respectively. The temperature of both injector and detector were kept at 300°C and the temperature program was initial temperature 115°C for 2 minutes, increased at 10 °C/min to 200°C and hold at this temperature for 16 minutes, and finally increased at 60°C/min to 240°C for 2 minutes (total run time: 29.2 minutes). Samples were analysed by using ChemStation software and Microsoft Excel.
Time frame: Change in total lipids of EVs after intake period of 12 weeks
Plasma Total Phospholipids Analysis
A 400μl aliquot of frozen PFP was defrosted and centrifuged to remove denatured protein. The 400μl of 0.9% NaCl was added to the PFP sample to make up 800μl in total, and 30μg of phosphatidylcholine (PC) and 15μg of phosphatidylethanolamine (PE) internal standards were then added for the quantitative analysis. After lipid extraction, separation of PC and PE, and methyl esterification of plasma phospholipid extracts, samples were analysed by GC.
Time frame: Change of plasma total phospholipids after intake period of 12 weeks
Concentrations of Lipid Profile in Plasma
A 250μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and centrifuged at 500xg for 5 minutes at room temperature (Eppendorf Centrifuge 5415 R, DJBlabcare, United Kingdom). Then the sample was analysed by a RANDOX clinical analyser (RANDOX Daytona+ Analyser, Randox Laboratories Ltd, United Kingdom) for the concentration of TC, TAG, HDL-C, LDL-C and TC/HDL-C ratio.
Time frame: Change in concentrations of plasma lipid profile after intake period of 12 weeks
Concentrations of TC/HDL-C Ratio in Plasma
A 250μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and centrifuged at 500xg for 5 minutes at room temperature (Eppendorf Centrifuge 5415 R, DJBlabcare, United Kingdom). Then the sample was analysed by a RANDOX clinical analyser (RANDOX Daytona+ Analyser, Randox Laboratories Ltd, United Kingdom) for TC/HDL-C ratio.
Time frame: Change in concentrations of plasma TC/HDL-C ratio after intake period of 12 weeks
Blood Pressure
Subjects were asked to have a rest for 10 mins before blood pressure detection, and then blood pressure cuff was placed firmly on their upper left arms approximately 2 cm above the elbow with the indicator mark on the cuff over the brachial artery to start measurement. Subjects should put their arms at the level of the heart and should not speak and cross their legs during the measurement. Measurement was performed three times and waited for 2 mins between each reading ((Omron M2 Upper Arm Blood Pressure Monitor, OMRON Healthcare Europe BV, United Kingdom). The average of the three readings was taken to obtain the final result.
Time frame: Change in blood pressure after intake period of 12 weeks
Participants were recruited by using the Hugh Sinclair Unit of Human Nutrition volunteer database, emailing advertisements to staff and students of the University of Reading, to members of local community groups and to staff members in large local organisations and companies between Oct 2017 and March 2019. The first participant was enrolled on 16th Feb 2018 and the last participant was enrolled in March 2019.
| Milestone | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| Milestone | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| Milestone | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
Circulating EVs were first isolated to obtain fractions 7\~9 by size exclusion chromatography (SEC) using Izon qEV columns (Izon Science Ltd, Oxford, United Kingdom). Fractions were then diluted with PBS to maintain the recommended concentration range of particles (1\~10\*10\^8 vesicles/ml) before being analysed on NanoSight 300 (Malvern, Amesbury, United Kingdom). For each analysis, five videos, each of 60 seconds duration, were captured with the camera level at 13. Data were analysed using the instrument software NTA 3.20, which can identify individual particles and estimate their sizes based on the Stokes-Einstein Equation. Finally, a threshold of 70nm was set for NTA to ensure minimal interference by small lipoproteins.
| vesicles per ml blood | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Numbers of Circulating Total EVs in Platelet-free Plasma (PFP) Detected by Nanoparticle Tracking Analysis (NTA) | -2.9*10^10 ± 8.5*10^9 | 7.5*10^9 ± 4.4*10^9 |
A 5μl of PFP was added into nonsticky microcentrifuge tubes (Alpha Laboratories Ltd, Hampshire, United Kingdom), which contained 5μl FcR blocking reagent (Miltenyi Biotec Ltd, Surrey, United Kingdom) and Annexin V buffer and incubated for 15 minutes in the dark at room temperature. Antibodies and isotype-matched controls were then added and samples incubated for another 15 minutes in the dark at room temperature. After incubation, samples were diluted with 200μl Annexin V buffer and transferred into FACS flow tubes (BD Biosciences, Wokingham, United Kingdom), ready to be analysed by FCM. PS+EVs were identified as Annexin V+EVs when triggering on APC fluorescence.
| vesicles per ml blood | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Numbers of Total Phosphatidylserine Positive EVs (PS+EVs) in Platelet-free Plasma (PFP) Detected by Flow Cytometry (FCM) | -1.2*10^7 ± 2.0*10^6 | -3.0*10^5 ± 2.5*10^6 |
A 5μl of PFP was added into nonsticky microcentrifuge tubes (Alpha Laboratories Ltd, Hampshire, United Kingdom), which contained 5μl FcR blocking reagent (Miltenyi Biotec Ltd, Surrey, United Kingdom) and Annexin V buffer and incubated for 15 minutes in the dark at room temperature. Antibodies and isotype-matched controls were then added and samples incubated for another 15 minutes in the dark at room temperature. After incubation, samples were diluted with 200μl Annexin V buffer and transferred into FACS flow tubes (BD Biosciences, Wokingham, United Kingdom), ready to be analysed by FCM. Platelet-derived EVs (PDEVs) were identified as Annexin V+EVs which also stained positive for CD41-PE in APC vs PE quadrant plot, and endothelial-derived EVs (EDEVs) were identified as Annexin V+EVs which also stained positive for CD105- eFluor450 in APC vs PB quadrant plot.
| vesicles per ml blood | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| PDEV numbers | -6.0*10^6 ± 1.5*10^6 | -3.0*10^5 ± 1.2*10^6 |
| EDEV numbers | -5.5*10^5 ± 1.5*10^5 | 2.9*10^5 ± 1.3*10^5 |
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
| min | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Pro-thrombotic Activities of Circulating EVs in PFP (Lag Time for Thrombin Generation) | 2.5 ± 0.5 | 1.2 ± 0.5 |
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
| nM | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Pro-thrombotic Activities of Circulating EVs in PFP (Peak Thrombin Concentration) | -16.2 ± 2.5 | -1.6 ± 2.0 |
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
| min | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Pro-thrombotic Activities of Circulating EVs in PFP (Time to Peak Thrombin Concentration) | 4.6 ± 1.0 | 0.3 ± 0.7 |
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
| nM/min | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Pro-thrombotic Activities of Circulating EVs in PFP (Velocity Index) | -1.1 ± 0.4 | -0.2 ± 0.2 |
A commercially available, plate-based thrombin generation assay was used to measure thrombin generation in either a standard, pooled vesicle and platelet-free plasma (termed vesicle-free plasma or VFP) or in the same VFP but with added circulating EVs from subjects in the intervention study. This enabled the assessment of TF-dependent thrombin generation specifically attributed to circulating EVs in samples from the intervention study. Results were presented as five variables: (i) lag-phase for initiation of thrombin generation after addition of the trigger (time to 1/6 of the peak height) (min); (ii) peak thrombin concentration (nM); (iii) time to reach the peak (min); (iv) velocity index, defined as = \[peak height/(time to peak - lag time)\] and (v) area under the curve, defined as endogenous thrombin potential (ETP) (expressed as nM thrombin × min)
| nM thrombin × min | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Pro-thrombotic Activities of Circulating EVs in PFP (Endogenous Thrombin Potential) | -437.2 ± 70.1 | -60.8 ± 66.2 |
96-well high-throughput aggregometry technique, allowing testing of a wide range of concentrations of different agonists, was used to examine the influence of n-3 PUFA supplementation on platelet function. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) from each study visit was used in the platelet aggregation assay using pre-prepared 96-well microplates, containing the agonists (ADP, EPI, TRAP-6 and U46619). Dose-response curves in response to each agonist were obtained and results were represented as a LogEC50 (log concentration of agonist, M, giving a response halfway between maximum and minimum aggregation).
| log(M) | Placebo Capsules | Fish Oil Capsules |
|---|---|---|
| ADP logEC50 | -0.17 ± 0.29 | -0.078 ± 0.11 |
| Epinephrine logEC50 | -0.36 ± 0.24 | 0.16 ± 0.17 |
| TRAP-6 logEC50 | 0.20 ± 0.18 | 0.058 ± 0.16 |
| U46619 logEC50 | 0.14 ± 0.30 | -0.37 ± 0.25 |
96-well high-throughput aggregometry technique, allowing testing of a wide range of concentrations of different agonists, was used to examine the influence of n-3 PUFA supplementation on platelet function. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) from each study visit was used in the platelet aggregation assay using pre-prepared 96-well microplates, containing the agonists (CRP-XL). Dose-response curves in response to each agonist were obtained and results were represented as a LogEC50 (log concentration of agonist, mg/ml, giving a response halfway between maximum and minimum aggregation).
| log (mg/ml) | Placebo Capsules | Fish Oil Capsules |
|---|---|---|
| Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay (CRP-XL Log EC50) | -0.39 ± 0.20 | 0.032 ± 0.27 |
Ex vivo thrombus formation was measured by the addition of in vitro-generated PDEVs from stimulated platelets into whole blood under flow. Results were presented as three variables: (i) endpoint for ex vivo thrombus formation (FU); (ii) endpoint for ex vivo thrombus formation (FU); (iii) area under curve.
| FU | Intervention | Placebo |
|---|---|---|
| Endpoint of thrombu formation | -14.3 ± 13.4 | 9.9 ± 9.8 |
| Maximum of thrombus formation | -1.3 ± 16.1 | 20.6 ± 11.1 |
Ex vivo thrombus formation was measured by the addition of in vitro-generated PDEVs from stimulated platelets into whole blood under flow. Results were presented as three variables: (i) endpoint for ex vivo thrombus formation (FU); (ii) endpoint for ex vivo thrombus formation (FU); (iii) area under curve.
| FU x min | Intervention | Placebo |
|---|---|---|
| Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Area Under Curve) | -945 ± 4843 | 2502 ± 3587 |
A 500μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and subjected to SEC for the isolation and purification of EVs. The fractions 7\~9 were pooled together, and 800μl of pooled fractions was prepared for total lipid extraction and methyl esterification. The EV total lipid methyl esters were then analysed by gas chromatography on a Hewlett-Packard 6890 series GC (Hewlett-Packard, California, United States), with the following protocol: split ratio was set as 30:1 for plasma and EV analysis. The injection volume was 1μl for plasma and 5μl for EVs, respectively. The temperature of both injector and detector were kept at 300°C and the temperature program was initial temperature 115°C for 2 minutes, increased at 10 °C/min to 200°C and hold at this temperature for 16 minutes, and finally increased at 60°C/min to 240°C for 2 minutes (total run time: 29.2 minutes). Samples were analysed by using ChemStation software and Microsoft Excel.
| g/100g total fatty acids | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| EPA | 0.9 ± 0.1 | -0.1 ± 0.1 |
| DHA | 1.0 ± 0.1 | -0.02 ± 0.1 |
| DPA | 0.2 ± 0.02 | 0.04 ± 0.03 |
| Total n-3 PUFA | 2.5 ± 0.3 | 0.2 ± 0.2 |
| Oleic acid | -1.9 ± 0.4 | 0.4 ± 0.7 |
| AA | -0.4 ± 0.1 | 0.1 ± 0.1 |
| Total MUFA | -2.2 ± 0.4 | 0.2 ± 0.8 |
A 400μl aliquot of frozen PFP was defrosted and centrifuged to remove denatured protein. The 400μl of 0.9% NaCl was added to the PFP sample to make up 800μl in total, and 30μg of phosphatidylcholine (PC) and 15μg of phosphatidylethanolamine (PE) internal standards were then added for the quantitative analysis. After lipid extraction, separation of PC and PE, and methyl esterification of plasma phospholipid extracts, samples were analysed by GC.
| g/100g total fatty acids | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| EPA | 2.9 ± 0.2 | -0.1 ± 0.1 |
| DHA | 2.4 ± 0.2 | -0.1 ± 0.1 |
| DPA | 0.2 ± 0.04 | -0.1 ± 0.02 |
| Total n-3 PUFA | 5.6 ± 0.4 | -0.2 ± 0.1 |
| Linoleic acid | -2.0 ± 0.4 | 0.4 ± 0.2 |
| DGLA | -0.8 ± 0.1 | 0.04 ± 0.1 |
| Total MUFA | -1.0 ± 0.4 | -0.1 ± 0.4 |
A 250μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and centrifuged at 500xg for 5 minutes at room temperature (Eppendorf Centrifuge 5415 R, DJBlabcare, United Kingdom). Then the sample was analysed by a RANDOX clinical analyser (RANDOX Daytona+ Analyser, Randox Laboratories Ltd, United Kingdom) for the concentration of TC, TAG, HDL-C, LDL-C and TC/HDL-C ratio.
| mmol/L | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| TAG | -0.1 ± 0.04 | 0.03 ± 0.04 |
| LDL-C | 0.1 ± 0.06 | -0.1 ± 0.04 |
| TC | 0.1 ± 0.07 | -0.02 ± 0.05 |
| HDL-C | 0.06 ± 0.02 | 0.04 ± 0.02 |
| TC/HDL-C ratio | -0.04 ± 0.05 | -0.1 ± 0.04 |
A 250μl aliquot of frozen PFP was defrosted at room temperature using a roller mixer and centrifuged at 500xg for 5 minutes at room temperature (Eppendorf Centrifuge 5415 R, DJBlabcare, United Kingdom). Then the sample was analysed by a RANDOX clinical analyser (RANDOX Daytona+ Analyser, Randox Laboratories Ltd, United Kingdom) for TC/HDL-C ratio.
| ratio | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Concentrations of TC/HDL-C Ratio in Plasma | -0.04 ± 0.05 | -0.1 ± 0.04 |
Subjects were asked to have a rest for 10 mins before blood pressure detection, and then blood pressure cuff was placed firmly on their upper left arms approximately 2 cm above the elbow with the indicator mark on the cuff over the brachial artery to start measurement. Subjects should put their arms at the level of the heart and should not speak and cross their legs during the measurement. Measurement was performed three times and waited for 2 mins between each reading ((Omron M2 Upper Arm Blood Pressure Monitor, OMRON Healthcare Europe BV, United Kingdom). The average of the three readings was taken to obtain the final result.
| mmHg | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| SBP | -6.7 ± 1.0 | 3.4 ± 1.7 |
| DBP | -2.9 ± 0.7 | 0.9 ± 0.9 |
Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fish Oil Capsules | 0/40 (0%) | 0/40 (0%) | 1/40 (2.5%) |
| Placebo Capsules | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Event | Fish Oil Capsules | Placebo Capsules |
|---|---|---|
| Lump above the site of venepunctureGeneral disorders | 1/40 | 0/40 |
| Age, Continuous(years) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Median | 64.3 (62.8 to 65.8) | 65.0 (62.6 to 66.6) | 65.0 (62.0 to 66.9) |
| Sex: Female, Male(Participants) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Female | 5 | 11 | 16 |
| Male | 15 | 9 | 24 |
| Race/Ethnicity, Customized(participants) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| White British | 20 | 20 | 40 |
| Region of Enrollment(participants) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| United Kingdom | 20 | 20 | 40 |
| Body Mass Index(kg/m^2) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Mean | 25.0 ± 2.8 | 25.7 ± 3.1 | 25.4 ± 2.9 |
| Systolic Blood Pressure(mmHg) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Mean | 130.5 ± 11.5 | 137.1 ± 15.8 | 134.0 ± 14.2 |
| Diastolic Blood Pressure(mmHg) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Mean | 78.5 ± 7.3 | 79.1 ± 10.7 | 78.8 ± 9.1 |
| Blood Cholesterol Concentration(mmol/L) | Fish Oil Capsules, Then Placebo Capsules | Placebo Capsules, Then Fish Oil Capsules | Total |
|---|---|---|---|
| Mean | 5.8 ± 0.9 | 6.2 ± 1.1 | 6.0 ± 1.0 |
4 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Reading